Clinical Trial Update: AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 study of cediranib (AZD2171) in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• AZD2171 (cediranib) (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-11-09